<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36675479</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12020552</ELocationID><Abstract><AbstractText>Background: Endotheliopathy is a common pathologic finding in patients with acute and long COVID-19. It may be associated with disease severity and predispose patients to long-term complications. Plasma levels of a proteoglycan, syndecan-1, are found to be significantly elevated in patients with COVID-19, but its roles in assessing disease severity and predicting long-term outcome are not fully understood. Methods: A total of 124 consecutive hospitalized patients with SARS-CoV-2 infection were prospectively enrolled and blood samples were collected on admission (T1), 3&#x2212;4 days following treatment (T2), and 1&#x2212;2 days prior to discharge or death (T3). Plasma levels of syndecan-1 were determined using an immunosorbent assay; various statistical analyses were performed to determine the association between plasma syndecan-1 levels and disease severity or the 60-day mortality rate. Results: Compared with those in the healthy controls, plasma levels of syndecan-1 in patients with critical COVID-19 were significantly higher (p &lt; 0.0001). However, there was no statistically significant difference among patients with different disease severity (p &gt; 0.05), resulting from large individual variability. Longitudinal analysis demonstrated that while the levels fluctuated during hospitalization in all patients, plasma syndecan-1 levels were persistently elevated from baseline in critical COVID-19 patients. Cox proportional hazard regression analyses revealed that elevated plasma levels of syndecan-1 (&gt;260 ng/mL at T1, &gt;1018 ng/mL at T2, and &gt;461 ng/mL at T3) were significantly associated with the 60-day mortality rate. Conclusions: Endotheliopathy, marked by glycocalyx degradation and elevated plasma syndecan-1, occurs in nearly all hospitalized patients with SARS-CoV-2 infection; elevated plasma syndecan-1 is associated with increased mortality in COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-5916-9239</Identifier><AffiliationInfo><Affiliation>Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zhan</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2378-3813</Identifier><AffiliationInfo><Affiliation>Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bignotti</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>X Long</ForeName><Initials>XL</Initials><Identifier Source="ORCID">0000-0003-1680-5295</Identifier><AffiliationInfo><Affiliation>Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Reproductive and Developmental Sciences, The University of Kansas Medical Center, Kansas City, KS 66160, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">glycocalyx degradation</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">syndecan-1</Keyword></KeywordList><CoiStatement>X.L.Z. is a consultant and a member of the advisory boards for Alexion, Sanofi, and Takeda, as well as the founder of Clotsolution. Other authors have nothing to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36675479</ArticleId><ArticleId IdType="pmc">PMC9865511</ArticleId><ArticleId IdType="doi">10.3390/jcm12020552</ArticleId><ArticleId IdType="pii">jcm12020552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xu S.-W., Ilyas I., Weng J.-P. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms, and potential therapies. Acta Pharmacol. Sin. 2022:1&#x2013;15. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Aird W.C. Endothelium as an organ system. Crit. Care Med. 2004;32:S271&#x2013;S279. doi: 10.1097/01.CCM.0000129669.21649.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000129669.21649.40</ArticleId><ArticleId IdType="pubmed">15118530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellenthal K.E.M., Brabenec L., Wagner N.-M. Regulation and Dysregulation of Endothelial Permeability during Systemic Inflammation. Cells. 2022;11:1935. doi: 10.3390/cells11121935.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11121935</ArticleId><ArticleId IdType="pmc">PMC9221661</ArticleId><ArticleId IdType="pubmed">35741064</ArticleId></ArticleIdList></Reference><Reference><Citation>Petruzziello-Pellegrini T.N., Moslemi-Naeini M., Marsden P.A. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Virulence. 2013;4:556&#x2013;563. doi: 10.4161/viru.26143.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.26143</ArticleId><ArticleId IdType="pmc">PMC5359733</ArticleId><ArticleId IdType="pubmed">23955166</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell R.T., McDaniel J.K., Cao W., Shroyer M., Wagener B.M., Pittet J.-F., Zheng X.L. Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma. Thromb. Haemost. 2018;118:676&#x2013;687. doi: 10.1055/s-0038-1636528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1636528</ArticleId><ArticleId IdType="pmc">PMC6433136</ArticleId><ArticleId IdType="pubmed">29618154</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., Kolesnick R. Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice. Science. 2001;293:293&#x2013;297. doi: 10.1126/science.1060191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1060191</ArticleId><ArticleId IdType="pubmed">11452123</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Ierssel S.H., Conraads V.M., Van Craenenbroeck E.M., Liu Y., Maas A.I., Parizel P.M., Hoymans V.Y., Vrints C.J., Jorens P.G. Endothelial dysfunction in acute brain injury and the development of cerebral ischemia. J. Neurosci. Res. 2015;93:866&#x2013;872. doi: 10.1002/jnr.23566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23566</ArticleId><ArticleId IdType="pubmed">25677574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog D.A., Storey R.F., Gurbel P.A., Tantry U.S., Berger J.S., Chan M.Y., Duerschmied D., Smyth S.S., Parker W.A.E., Ajjan R.A., et al. Current and novel biomarkers of thrombotic risk in COVID-19: A Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat. Rev. Cardiol. 2022;19:475&#x2013;495. doi: 10.1038/s41569-021-00665-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00665-7</ArticleId><ArticleId IdType="pmc">PMC8757397</ArticleId><ArticleId IdType="pubmed">35027697</ArticleId></ArticleIdList></Reference><Reference><Citation>Orea-Tejada A., S&#xe1;nchez-Moreno C., Aztatzi-Aguilar O.G., Sierra-Vargas M.P., Gonz&#xe1;lez-Islas D., Debray-Garc&#xed;a Y., Ortega-Romero M.S., Keirns-Davis C., Cornejo-Cornejo L., Aguilar-Meza J. Plasma Endothelial and Oxidative Stress Biomarkers Associated with Late Mortality in Hospitalized COVID-19 Patients. J. Clin. Med. 2022;11:3950. doi: 10.3390/jcm11143950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11143950</ArticleId><ArticleId IdType="pmc">PMC9319197</ArticleId><ArticleId IdType="pubmed">35887714</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrianto, Al-Farabi M.J., Nugraha R.A., Marsudi B.A., Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Microvasc. Res. 2021;138:104224. doi: 10.1016/j.mvr.2021.104224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2021.104224</ArticleId><ArticleId IdType="pmc">PMC8279939</ArticleId><ArticleId IdType="pubmed">34273359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Li L., Chen Y., Ma J., Yang Y., Aodeng S., Cui Q., Wen K., Xiao M., Xie J., et al. Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19. Mol. Med. 2021;27:151. doi: 10.1186/s10020-021-00412-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-021-00412-1</ArticleId><ArticleId IdType="pmc">PMC8640509</ArticleId><ArticleId IdType="pubmed">34861818</ArticleId></ArticleIdList></Reference><Reference><Citation>Betteridge K.B., Arkill K.P., Neal C.R., Harper S.J., Foster R.R., Satchell S.C., Bates D.O., Salmon A.J.H. Sialic acids regulate microvessel permeability, revealed by novel in vivo studies of endothelial glycocalyx structure and function. J. Physiol. 2017;595:5015&#x2013;5035. doi: 10.1113/JP274167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP274167</ArticleId><ArticleId IdType="pmc">PMC5538239</ArticleId><ArticleId IdType="pubmed">28524373</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler M.J., Ramnath R., Kadoya H., Desposito D., Riquier-Brison A., Ferguson J.K., Onions K.L., Ogier A.S., ElHegni H., Coward R., et al. Aldosterone induces albuminuria via matrix metalloproteinase&#x2013;dependent damage of the endothelial glycocalyx. Kidney Int. 2019;95:94&#x2013;107. doi: 10.1016/j.kint.2018.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.08.024</ArticleId><ArticleId IdType="pmc">PMC6506575</ArticleId><ArticleId IdType="pubmed">30389198</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Y.H.-F., Aquino R.S., Park P.W. Molecular functions of syndecan-1 in disease. Matrix Biol. 2012;31:3&#x2013;16. doi: 10.1016/j.matbio.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2011.10.001</ArticleId><ArticleId IdType="pmc">PMC3568394</ArticleId><ArticleId IdType="pubmed">22033227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobayen G., Dhutia A., Clarke C., Prendecki M., McAdoo S., Keniyopoullos R., Malik T., Laffan M., Willicombe M., McKinnon T. Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis. Res. Pract. Thromb. Haemost. 2021;5:e12582. doi: 10.1002/rth2.12582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12582</ArticleId><ArticleId IdType="pmc">PMC8435526</ArticleId><ArticleId IdType="pubmed">34532629</ArticleId></ArticleIdList></Reference><Reference><Citation>Beurskens D.M., Bol M.E., Delhaas T., Van de Poll M., Reutelingsperger C.P., Nicolaes G.A., Sels J.-W.E. Decreased endothelial glycocalyx thickness is an early predictor of mortality in sepsis. Anaesth. Intensiv. Care. 2020;48:221&#x2013;228. doi: 10.1177/0310057X20916471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0310057X20916471</ArticleId><ArticleId IdType="pmc">PMC7328096</ArticleId><ArticleId IdType="pubmed">32486831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa F., Oi Y., Nakajima K., Matsumura R., Nakagawa T., Miyagawa T., Sakai K., Saji R., Taniguchi H., Takahashi K., et al. Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19. Thromb. J. 2021;19:55. doi: 10.1186/s12959-021-00308-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-021-00308-4</ArticleId><ArticleId IdType="pmc">PMC8366156</ArticleId><ArticleId IdType="pubmed">34399775</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M., Bottino N., Tagliabue P., Grasselli G., Novembrino C., Chantarangkul V., Pesenti A., Peyvandi F., Tripodi A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 2020;18:1738&#x2013;1742. doi: 10.1111/jth.14850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14850</ArticleId><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Sui J., Zheng X.L. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura. Blood Adv. 2020;4:5378&#x2013;5388. doi: 10.1182/bloodadvances.2020003065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003065</ArticleId><ArticleId IdType="pmc">PMC7656933</ArticleId><ArticleId IdType="pubmed">33141886</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Z., Liu F., Blair R., Wang C., Yang H., Mudd J., Currey J.M., Iwanaga N., He J., Mi R., et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics. 2021;11:8076&#x2013;8091. doi: 10.7150/thno.61810.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.61810</ArticleId><ArticleId IdType="pmc">PMC8315069</ArticleId><ArticleId IdType="pubmed">34335981</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Y., Lei T., Patel P.S., Lee C.H., Monaghan-Nichols P., Xin H.-B., Qiu J., Fu M. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin. J. Virol. 2021;95:e0139621. doi: 10.1128/JVI.01396-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01396-21</ArticleId><ArticleId IdType="pmc">PMC8577385</ArticleId><ArticleId IdType="pubmed">34549987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambadiari V., Mitrakou A., Kountouri A., Thymis J., Katogiannis K., Korakas E., Varlamos C., Andreadou I., Tsoumani M., Triantafyllidi H., et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur. J. Heart Fail. 2021;23:1916&#x2013;1926. doi: 10.1002/ejhf.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2326</ArticleId><ArticleId IdType="pmc">PMC8426810</ArticleId><ArticleId IdType="pubmed">34415085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chioh F.W., Fong S.-W., Young B.E., Wu K.-X., Siau A., Krishnan S., Chan Y.-H., Carissimo G., Teo L.L., Gao F., et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife. 2021;10:e64909. doi: 10.7554/eLife.64909.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.64909</ArticleId><ArticleId IdType="pmc">PMC7987341</ArticleId><ArticleId IdType="pubmed">33752798</ArticleId></ArticleIdList></Reference><Reference><Citation>Masola V., Zaza G., Arduini A., Onisto M., Gambaro G. Endothelial Glycocalyx as a Regulator of Fibrotic Processes. Int. J. Mol. Sci. 2021;22:2996. doi: 10.3390/ijms22062996.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22062996</ArticleId><ArticleId IdType="pmc">PMC7999025</ArticleId><ArticleId IdType="pubmed">33804258</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyfuss J.L., Regatieri C.V., Jarrouge T.R., Cavalheiro R.P., Sampaio L.O., Nader H.B. Heparan sulfate proteoglycans: Structure, protein interactions and cell signaling. Ann. Acad. Bras. Cienc. 2009;81:409&#x2013;429. doi: 10.1590/S0001-37652009000300007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S0001-37652009000300007</ArticleId><ArticleId IdType="pubmed">19722012</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl K., Gronski P.A., Kiyan Y., Seeliger B., Bertram A., Pape T., Welte T., Hoeper M.M., Haller H., David S. Injury to the Endothelial Glycocalyx in Critically Ill Patients with COVID-19. Am. J. Respir. Crit. Care Med. 2020;202:1178&#x2013;1181. doi: 10.1164/rccm.202007-2676LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202007-2676LE</ArticleId><ArticleId IdType="pmc">PMC7560808</ArticleId><ArticleId IdType="pubmed">32833500</ArticleId></ArticleIdList></Reference><Reference><Citation>Potje S.R., Costa T.J., Fraga-Silva T.F., Martins R.B., Benatti M.N., Almado C.E., De S&#xe1; K.S., Bonato V.L., Arruda E., Louzada-Junior P., et al. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients. Life Sci. 2021;276:119376. doi: 10.1016/j.lfs.2021.119376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119376</ArticleId><ArticleId IdType="pmc">PMC7997864</ArticleId><ArticleId IdType="pubmed">33781826</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L., Cheng S., Sol W.M., Van der Velden A.I., Vink H., Rabelink T.J., Berg B.M.V.D. Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit. ERJ Open Res. 2022;8:00652-2021. doi: 10.1183/23120541.00652-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00652-2021</ArticleId><ArticleId IdType="pmc">PMC8958944</ArticleId><ArticleId IdType="pubmed">35509442</ArticleId></ArticleIdList></Reference><Reference><Citation>Drost C.C., Rovas A., Osiaevi I., Rauen M., Van der Vlag J., Buijsers B., Salmenov R., Lukasz A., Pavenst&#xe4;dt H., Linke W.A., et al. Heparanase Is a Putative Mediator of Endothelial Glycocalyx Damage in COVID-19&#x2014;A Proof-of-Concept Study. Front. Immunol. 2022;13:916512. doi: 10.3389/fimmu.2022.916512.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.916512</ArticleId><ArticleId IdType="pmc">PMC9226442</ArticleId><ArticleId IdType="pubmed">35757776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez E.G., Ostrowski S.R., Cardenas J.C., Baer L.A., Tomasek J.S., Henriksen H.H., Stensballe J., Cotton B.A., Holcomb J.B., Johansson P.I., et al. Syndecan-1: A Quantitative Marker for the Endotheliopathy of Trauma. J. Am. Coll. Surg. 2017;225:419&#x2013;427. doi: 10.1016/j.jamcollsurg.2017.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2017.05.012</ArticleId><ArticleId IdType="pubmed">28579548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipowsky H.H., Sah R., Lescanic A. Relative roles of doxycycline and cation chelation in endothelial glycan shedding and adhesion of leukocytes. Am. J. Physiol. Circ. Physiol. 2011;300:H415&#x2013;H422. doi: 10.1152/ajpheart.00923.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00923.2010</ArticleId><ArticleId IdType="pmc">PMC3044056</ArticleId><ArticleId IdType="pubmed">21148759</ArticleId></ArticleIdList></Reference><Reference><Citation>Popova T.G., Millis B., Bailey C., Popov S.G. Platelets, inflammatory cells, von Willebrand factor, syndecan-1, fibrin, fibronectin, and bacteria co-localize in the liver thrombi of Bacillus anthracis-infected mice. Microb. Pathog. 2012;52:1&#x2013;9. doi: 10.1016/j.micpath.2011.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2011.08.004</ArticleId><ArticleId IdType="pubmed">22001909</ArticleId></ArticleIdList></Reference><Reference><Citation>Smart L., Bosio E., Macdonald S., Dull R., Fatovich D., Neil C., Arendts G. Glycocalyx biomarker syndecan-1 is a stronger predictor of respiratory failure in patients with sepsis due to pneumonia, compared to endocan. J. Crit. Care. 2018;47:93&#x2013;98. doi: 10.1016/j.jcrc.2018.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2018.06.015</ArticleId><ArticleId IdType="pubmed">29936329</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampoor S., Zahednasab H., Farahmand M., Mirzaei R., Zamani F., Tabibzadeh A., Bouzari B., Ajdarkosh H., Nikkhah M., Hashemi M.R., et al. A possible pathogenic role of Syndecan-1 in the pathogenesis of coronavirus disease 2019 (COVID-19) Int. Immunopharmacol. 2021;97:107684. doi: 10.1016/j.intimp.2021.107684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107684</ArticleId><ArticleId IdType="pmc">PMC8052477</ArticleId><ArticleId IdType="pubmed">33932696</ArticleId></ArticleIdList></Reference><Reference><Citation>Koz&#x142;owski P., &#x15a;miarowski M., Przyborska W., Zemlik K., Ma&#x142;ecka-Gie&#x142;dowska M., Leszczy&#x144;ska A., Garley M., Ciepiela O. Mild-to-Moderate COVID-19 Convalescents May Present Pro-Longed Endothelium Injury. J. Clin. Med. 2022;11:6461. doi: 10.3390/jcm11216461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11216461</ArticleId><ArticleId IdType="pmc">PMC9658558</ArticleId><ArticleId IdType="pubmed">36362687</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>